COMPANY

Kinaset Therapeutics

Keywords: severe asthma Asthma COPD Frevecitinib KN-002

Location: Medfield, MA · source · Jul 17, 2023

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series B · $103M · announced Jan 10, 2026 Company release ↗
Source quote
- Jan 10, 2026 · Company release ↗
  “Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel”

Raises announced in these releases: $103M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Jul 16, 2026 Trial start Phase 2: A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma source ↗
Jan 10, 2026 Raise Series B · $103M source ↗
Jul 30, 2021 Trial start Phase 1: Single and Multiple Ascending Dose Study of KN-002 source ↗

Nov 30, 2027 (ESTIMATED) · Phase 2 · A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma · NCT07532265

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07532265	A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma	Phase 2	Recruiting	Jul 16, 2026	Nov 30, 2027 (estimated)
NCT05006521	Single and Multiple Ascending Dose Study of KN-002	Phase 1	Completed	Jul 30, 2021	Dec 20, 2023 (actual)

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of Atlas Venture (captured Oct 12, 2026). portfolio page ↗